Patent · US Expired

3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators

US5959123A · kind A · utility

26Cited by
0References
29Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 22, 1997
Grant dateSep 28, 1999
Priority date
Expiry dateSep 22, 2017

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is based on the discovery that certain 3,4-disubstituted-azetidin-2-one derivatives exhibit excellent cysteine proteinase inhibitory activity which can be used for treatment of different diseases such as muscular dystrophy, myocardial infarction, bone resorption, arthritis, cancer metastasis, pulmonary emphysema, septic shock, cerebral ischemia, memory function, Alzheimer and cataract, malaria, glomerular basement membrane degradation, bacterial infection, inflammatory diseases, parasitic infections, and viral infections. In accordance to the present invention, there is provided a 3,4-disubstituted-azetidin-2-one derivatives of formula I, wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein, or a pharmaceutically acceptable salt thereof. ##STR1##

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.